vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
Dominari Holdings Inc. is the larger business by last-quarter revenue ($30.1M vs $27.5M, roughly 1.1× Sanara MedTech Inc.). Sanara MedTech Inc. runs the higher net margin — -5.9% vs -438.1%, a 432.3% gap on every dollar of revenue. On growth, Dominari Holdings Inc. posted the faster year-over-year revenue change (220.4% vs 4.6%). Over the past eight quarters, Dominari Holdings Inc.'s revenue compounded faster (369.1% CAGR vs 21.8%).
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
DOMH vs SMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $27.5M |
| Net Profit | $-131.8M | $-1.6M |
| Gross Margin | — | 93.2% |
| Operating Margin | -8.9% | 23.5% |
| Net Margin | -438.1% | -5.9% |
| Revenue YoY | 220.4% | 4.6% |
| Net Profit YoY | -12426.2% | 5.3% |
| EPS (diluted) | $-6.94 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | $27.5M | ||
| Q3 25 | $50.8M | $26.3M | ||
| Q2 25 | $34.1M | $25.8M | ||
| Q1 25 | $8.1M | $23.4M | ||
| Q4 24 | $9.4M | $26.3M | ||
| Q3 24 | $4.0M | $21.7M | ||
| Q2 24 | $6.2M | $20.2M | ||
| Q1 24 | $1.4M | $18.5M |
| Q4 25 | $-131.8M | $-1.6M | ||
| Q3 25 | $125.2M | $-30.4M | ||
| Q2 25 | $16.6M | $-2.0M | ||
| Q1 25 | $-32.5M | $-3.5M | ||
| Q4 24 | $1.1M | $-1.7M | ||
| Q3 24 | $-4.2M | $-2.9M | ||
| Q2 24 | $-6.1M | $-3.5M | ||
| Q1 24 | $-5.4M | $-1.8M |
| Q4 25 | — | 93.2% | ||
| Q3 25 | — | 92.9% | ||
| Q2 25 | — | 92.5% | ||
| Q1 25 | — | 92.2% | ||
| Q4 24 | — | 91.4% | ||
| Q3 24 | — | 90.8% | ||
| Q2 24 | — | 90.0% | ||
| Q1 24 | — | 89.8% |
| Q4 25 | -8.9% | 23.5% | ||
| Q3 25 | -3.1% | 11.2% | ||
| Q2 25 | -57.0% | -0.1% | ||
| Q1 25 | -394.6% | -8.9% | ||
| Q4 24 | 0.4% | 18.6% | ||
| Q3 24 | -79.1% | 3.6% | ||
| Q2 24 | -44.3% | -14.3% | ||
| Q1 24 | -205.2% | -8.3% |
| Q4 25 | -438.1% | -5.9% | ||
| Q3 25 | 246.4% | -115.5% | ||
| Q2 25 | 48.7% | -7.8% | ||
| Q1 25 | -400.5% | -15.1% | ||
| Q4 24 | 11.4% | -6.5% | ||
| Q3 24 | -104.2% | -13.2% | ||
| Q2 24 | -99.1% | -17.4% | ||
| Q1 24 | -398.0% | -9.5% |
| Q4 25 | $-6.94 | $-0.32 | ||
| Q3 25 | $7.27 | $-3.40 | ||
| Q2 25 | $1.12 | $-0.23 | ||
| Q1 25 | $-3.02 | $-0.41 | ||
| Q4 24 | $0.21 | $-0.18 | ||
| Q3 24 | $-0.67 | $-0.34 | ||
| Q2 24 | $-1.01 | $-0.41 | ||
| Q1 24 | $-0.91 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $16.6M |
| Total DebtLower is stronger | — | $46.0M |
| Stockholders' EquityBook value | $69.4M | $5.9M |
| Total Assets | $112.9M | $72.9M |
| Debt / EquityLower = less leverage | — | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | $16.6M | ||
| Q3 25 | $176.2M | $14.9M | ||
| Q2 25 | $28.2M | $17.0M | ||
| Q1 25 | $18.9M | $20.7M | ||
| Q4 24 | $8.2M | $15.9M | ||
| Q3 24 | $7.2M | $16.3M | ||
| Q2 24 | $12.1M | $6.2M | ||
| Q1 24 | $7.1M | $2.8M |
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
| Q4 25 | $69.4M | $5.9M | ||
| Q3 25 | $210.2M | $6.1M | ||
| Q2 25 | $88.6M | $35.4M | ||
| Q1 25 | $42.4M | $36.7M | ||
| Q4 24 | $39.9M | $39.4M | ||
| Q3 24 | $38.3M | $39.8M | ||
| Q2 24 | $42.4M | $41.7M | ||
| Q1 24 | $47.7M | $43.3M |
| Q4 25 | $112.9M | $72.9M | ||
| Q3 25 | $223.4M | $71.1M | ||
| Q2 25 | $109.3M | $98.8M | ||
| Q1 25 | $52.3M | $96.4M | ||
| Q4 24 | $47.1M | $88.1M | ||
| Q3 24 | $43.4M | $88.5M | ||
| Q2 24 | $49.1M | $73.4M | ||
| Q1 24 | $52.2M | $70.9M |
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $3.9M |
| Free Cash FlowOCF − Capex | — | $3.9M |
| FCF MarginFCF / Revenue | — | 14.0% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | $3.9M | ||
| Q3 25 | $-4.9M | $2.2M | ||
| Q2 25 | $-353.0K | $2.7M | ||
| Q1 25 | $1.2M | $-2.0M | ||
| Q4 24 | $-16.7M | $932.0K | ||
| Q3 24 | $-4.7M | $2.1M | ||
| Q2 24 | $1.4M | $-1.4M | ||
| Q1 24 | $-8.6M | $-1.6M |
| Q4 25 | — | $3.9M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | — | $902.7K | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | — | $859.9K | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | — | $-1.5M | ||
| Q1 24 | — | $-1.7M |
| Q4 25 | — | 14.0% | ||
| Q3 25 | — | 4.2% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | -15.9% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 9.4% | ||
| Q2 24 | — | -7.3% | ||
| Q1 24 | — | -9.0% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 4.0% | ||
| Q2 25 | — | 6.8% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.4% |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
